Slide 1: Noninvasive Accurate Lung Cancer Detection
Noninvasive Accurate Lung Cancer Detection Revolutionizing diagnostics with proprietary AI analysis of flow cytometry data SPRING 2026 INVESTOR PRESENTATION bioAffinity Technologies (Nasdaq: BIAF) |
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other The forward-looking statements made in this presentation are based on persons acting by or on behalf of bioAffinity Technologies made in connection bioAffinity Technolog
Slide 3: Lung Cancer Is A Global Problem and Large Market
Lung Cancer Is A Global Problem and Large Market Leading cause of cancer-related deaths 2.48 Million 1.8 Million Diagnostic Market Growth New cases worldwide annually1 Deaths annually1 2034 Projected Market Major Screening Need in the United States An estimated 19.3 million Americans should have ann
Slide 4: Early Detection of Lung Cancer Saves Lives
Early Detection of Lung Cancer Saves Lives Improving survival rates through timely intervention and accurate diagnosis Current Survival Rates In 2025, less than 30% of patients survived 5 years2 The Power of Early Detection Late-Stage Diagnosis 92% Most patients are diagnosed with late-stage cancer
Slide 5: CyPath Lung Platform
® CyPath Lung Platform Detecting Lung Cancer with Noninvasive Technology 92%* 87%* 99%* 88%* Sensitivity1 Specificity1 NPV1 Accuracy1 Proprietary AI Analysis Patient-Friendly & Physician-Focused Growing Platform Technology AI-driven algorithm analyzes complex flow At-home collection (no needles, no
Slide 6: CyPath Lung in Action: Patient Case Studies
® CyPath Lung in Action: Patient Case Studies* Demonstrating Detection at Curative Stage 1A & Averting Risky Procedures LIKELY MALIGNANCY LIKELY MALIGNANCY UNLIKELY MALIGNANCY "Gloria" "Paula" "James" Challenge: PET scan and serum markers Challenge: Bronchoscopy and non-diagnostic Challenge: 85-year
Slide 7: CyPath Lung in Action: Patient Case Studies
® CyPath Lung in Action: Patient Case Studies* Case Studies Demonstrate Cancer Detection In Surveillance Period; Earlier Detection of Malignant Ground Glass Nodule LIKELY MALIGNANCY LIKELY MALIGNANCY LIKELY MALIGNANCY "Joan" "Carol" "Helen" Challenge: Surveillance in high-risk Challenge: New pulmona
Slide 8: Compares Favorably to Standards of Care
Compares Favorably to Standards of Care Proven Clinical Utility To Help Detect Lung Cancer Noninvasively Lung Cancer Diagnostic Procedure or Test Sensitivity Specificity CyPath® Lung1 92% 87% Fine Needle Biopsy4 90% 75% Core Needle Biopsy4 89% 89% FDG PET imaging2 89% 75% Bronchoscopy3 88% 47% FDG =
Slide 9: Physician-Focused, Patient-Friendly, Reimbursed by Insurance
Physician-Focused, Patient-Friendly, Reimbursed by Insurance Ships Overnight @ Clinic @ Home @ Laboratory @ Clinic Physician orders CyPath® Patient videos, written AI-driven automated Physician receives results Lung test to ship to patient instructions and personal analysis of flow cytometry within
Slide 10: Interpreting the Report
Interpreting the Report Scale reflects cancer probability Reference Ranges >0.00 & <0.50 Unlikely >0.50 & < 1.00 Likely Signed by: Vibha Bhasin, MD bioAffinity Technologies (Nasdaq: BIAF) |
Slide 11: Significant Healthcare Savings
Significant Healthcare Savings Economic Impact Analysis 2024 study1 authored by pulmonologists practicing at Audie L. Murphy Memorial VA Hospital and Brooke Army Medical ® Center evaluated CyPath Lung’s potential economic impact if added to the standard of care. Medicare Patient Commercial Insurance
Slide 12: How the Test Works
How the Test Works Flow Cytometry Interrogates Lung Microenvironment Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP. Proprietary AI-Driven Platform Analysis Automated analysis identifies cell populat
Slide 13: Market Opportunity
Market Opportunity ® The U.S. market for CyPath Lung is poised for significant growth 2030 Market Opportunity Indeterminate Pulmonary Nodules 2.9 MM 2025 +62% 4.7 MM 2030 $470 MM The total number of indeterminate pulmonary nodules At 10% Market Share (IPNs) detected by lung cancer screening and inci
Slide 14: Market Opportunity
Market Opportunity CyPath® Lung Use for Surveillance of Lung Cancer Recurrence 2030 Market Opportunity $87 MM Lung Cancer Survivors 680,450 871,580 2025 +28% 2035 At 10% Market Share The total number of people living with lung cancer is projected to increase by 28% from 680,450 survivors in 2025 to
Slide 15: Revenue & Key Business Milestones Achieved in 2025
Revenue & Key Business Milestones Achieved in 2025 Jan '25 A Solid Foundation for Growth 99% Year-over-year increase in CyPath® Lung units sold Published multiple case Entered major VA Phased market Expanded indications 87% studies and physician testimonials medical centers with lung nodule Entered
Slide 16: Longitudinal Clinical Trial Launches in 2026
Longitudinal Clinical Trial Launches in 2026 2,000 ~20 Q1 2026 Patients Collection Sites Enrollment Underway Designed to assess CyPath® Lung performance for risk stratification, clinical decision-making, detection and survivor surveillance. Collection sites include VA and military medical centers (q
Slide 17: Building on a Successful Diagnostic Platform
Building on a Successful Diagnostic Platform Next in Pipeline: Companion Diagnostics for Asthma and COPD Quantifying Lung Inflammation for Improved Therapy Precision Diagnostics Match patients to effective 23 M 27 M treatments and monitor their effectiveness over time, Adults in the U.S. People in t
Slide 18: Management
Management Innovative, Experienced, Dedicated Executive Leadership Maria Zannes, JD Gordon Downie, MD, PhD Michael Edwards, MBA William Bauta, PhD Xavier Reveles, MS Founder, CEO & President Chief Medical Officer Chief Financial Officer Chief Science Officer Chief Operating Officer 30+ years C-suite
Slide 19: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations Steve Girgenti Jamie Platt, PhD Peter Knight John Oppenheimer, MD Executive Chairman Director Director Director Founded leading global healthcare 20+ years of diagnostic expertise, led Founding Partner of Gener
Slide 20: Contact Us
Maria Zannes Contact Us President & CEO mz@bioaffinitytech.com 505-400-9747 bioAffinity Technologies (Nasdaq: BIAF) |